Sunday, July 12, 2026

TGA / PMDA / NMPA · Asia-Pacific

glycopyrronium — TGA / PMDA / NMPA regulatory status

glycopyrronium (AXHIDROX) regulatory status in the Asia-Pacific is tracked from public TGA / PMDA / NMPA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: TGA approved · NMPA clinical trials.

Status snapshot

Status
TGA approved · NMPA clinical trials
Brand
AXHIDROX
Mechanism
Muscarinic acetylcholine receptor inhibitor
Structured fields
9

Sponsor / originator context: Novartis Pharmaceuticals. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.

Pharmacology context used for competitive intelligence: Muscarinic acetylcholine receptor inhibitor. This page is a status aggregation for professional reference — not prescribing advice.

Regional decision snapshot — TGA: approved; NMPA: clinical trials.

Linked evidence on this spoke: 6 published clinical programs and 1 related patent record. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.

Regulatory timeline

Regulator Region Status Date Source
TGA Australia approved Evidence
NMPA China clinical trials Evidence

Linked clinical programs

Program Phase Sponsor NCT
Glycopyrronium bromide Phase 3 Novartis India NCT00929110
01INDA2024 Phase 1 Anaxis Pharma 2024-514725-38-00
D5985C00008 Phase 1 AstraZeneca 2023-504089-43-00
D5985C00009 Phase 1 AstraZeneca 2023-509914-12-00
Glycopyrronium Approved Chinese Academy of NCT05265507
Glycopyrronium in Combination With Tropisetron Approved First People's Hospital NCT05331651

Related patents

Number Title Jurisdiction
10906871 Processes for making, and methods of using, glycopyrronium compounds US

Related hubs

FAQ

What is the TGA / PMDA / NMPA approval status of glycopyrronium?

glycopyrronium currently shows TGA approved · NMPA clinical trials in our Asia-Pacific regulatory index. Confirm on the official TGA / PMDA / NMPA label or EPAR before clinical or commercial use.

Where does NovaPharmaNews get glycopyrronium regulatory data?

Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.

How many clinical programs are linked to glycopyrronium?

This spoke lists 6 published programs associated with glycopyrronium in our pipeline index.